PRNewsWire
06 Aug 2026, 21:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities fraud class action lawsuit alleging the use of 'channel stuffing' to artificially inflate revenue. — Allegations of artificial revenue inflation are severe red flags for investors and often lead to significant valuation corrections.
-0.80The lawsuit alleges that ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Weak internal controls and undisclosed related party transactions suggest poor corporate governance and potential accounting irregularities.
-0.60The Rosen Law Firm has set a deadline of August 10, 2026, for investors to move to serve as lead plaintiff in the litigation. — While a procedural step, the active solicitation of lead plaintiffs indicates the litigation is progressing and seeking scale.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit alleging channel stuffing and misleading statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
6h ago
